Anemia is universal after allogeneic and autologous stem cell transplantation, with both increased red cell utilization and decreased production playing a role. This anemia sometimes is associated with a relative erythropoietin deficiency. In allogeneic stem cell transplantation, randomized trials have demonstrated improved erythropoiesis and a decrease in red cell transfusions in recombinant human erythropoietin (rHuEPO)-treated patients. Studies of rHuEPO in patients undergoing autologous stem cell transplants, however, have not shown a benefit. The role of rHuEPO in stem cell mobilization and treatment of delayed erythropoiesis has yet to be defined and further studies are needed. Bone Marrow Transplantation (2001) 27, 1011-1016.
in patients after autologous stem cell transplant, but markedly depressed at the time of marrow recovery in allogeneic transplant recipients. They also found that erythropoietin response to anemia was lower in patients who had acute GVHD, while chronic GVHD did not appear to affect erythropoietin response. 1, 2 Cytomegalovirus infection also was an independent predictor of an impaired erythropoietin response to anemia. Nephrotoxicity was more common in the allogeneic stem cell transplant patients compared to the autologous stem cell transplant patients. There was not a significant correlation, however, between renal function and impairment in the erythropoietin response to anemia. Abedi et al 3 found that erythropoietin blood concentrations were lower in patients who had received cyclosporine as prophylaxis for GVHD compared to patients receiving T celldepleted transplants. However, they did not find a correlation between acute GVHD and a decreased erythropoietin level. While patients with nephrotoxicity had lower erythropoietin blood concentration than patients without nephrotoxicity, the decreased erythropoietin levels in the cyclosporin A-treated patients was seen in patients with and without renal impairment. On the other hand, investigators at Johns Hopkins found that for any given degree of anemia, erythropoietin concentrations were depressed in both allogeneic and autologous stem cell transplant patients compared to iron deficient controls ( Figure 1 ). 4 
Table 1
Etiology of anemia during hematopoietic stem cell transplantation Increased RBC utilization/shortened RBC survival fever hemolysis, eg ABO or Rh incompatibility, 27 ,28 microangiopathy after cyclosporine, 29 hemolytic-uremic syndrome 30 hepatic veno-occlusive disease 31 Hemorrhage thrombocytopenia, especially when protracted, eg chemically-purged autografts, immune mechanisms, [32] [33] [34] or hepatic veno-occlusive disease 31 organ injury, eg hemorrhagic cystitis, [35] [36] [37] [38] [39] gastritis infection, eg adenovirus, 40 BK virus 38 GVHD of gastro-intestinal tract 41, 42 Inadequate production RBC impaired/inadequate erythropoietin response, drugs causing bone marrow suppression (ganciclovir, trimethoprimsulfamethoxazole) infection causing bone marrow suppression (cytomegalovirus, HHV6) The etiology for the inadequate erythropoietin response to anemia is unknown but may reflect toxic effects exerted upon erythropoietin-producing cells by drugs or infectious agents, or may be a result of direct suppression of erythropoietin production by cytokines. Tumor necrosis factor concentrations, elevated after stem cell transplant, 5 can suppress erythropoietin production in Hep3B cell lines. 6 Both cyclosporin A 7 as well as amphotericin B 8 can suppress erythropoietin production in model systems. Regardless of the etiology, the inadequate erythropoietin response to anemia after stem cell transplantation suggests that exogenous recombinant human erythropoietin (rHuEPO) treatment may be beneficial. 
Clinical studies of the use of rHuEPO after stem cell transplantation

Allogeneic stem cell transplantation
rHuEPO has been demonstrated to be well-tolerated and effective in the allogeneic stem cell transplant setting ( Table 2) . [9] [10] [11] Steegman and co-workers 11 randomly assigned patients to receive daily rHuEPO (100 units per kg days 0 to 7, then 150 units per kg days 7 to 30) or placebo. Thirteen subjects received rHuEPO and 11 patients received placebo for a period of more than 14 days and were considered evaluable. In the rHuEPO-treated group, times to reach reticulocyte counts of 1%, 5% and 20% were shorter and bone marrow erythroid cellularity was increased. Importantly, RBC transfusion requirement was decreased from a mean of 12 units to 4 units (P Ͻ 0.05) during the first 30 days after transplant. Additionally, time to platelet transfusion (Ͼ25 000/l) independence (19 days vs 31 days, P Ͻ 0.05) and a decrease in platelet units transfused (36 vs 138, P Ͻ 0.05) were significantly better in the rHuEPO-treated patients.
Klaesson and colleagues 9 prospectively compared rHuEPO (200 units per kg per day for 4 weeks followed by twice weekly for 4 weeks) or placebo in 50 hematologic malignancy patients undergoing stem cell transplant. rHuEPO dose was decreased to 100 units per kilogram when hemoglobin exceeded 10 g/dl and was discontinued when hemoglobin was greater than 12 g/dl. Five patients (three rHuEPO and two controls) died before day 28 and were not considered evaluable. RBCs were transfused to maintain a hemoglobin of greater than 7.0 g/dl and platelets were transfused to maintain a count of greater than 30 000/mm 3 . At the 2 month evaluation, mean hemoglobin in the rHuEPO-treated patients was higher compared to placebo-treated patients (10.0 g/dl vs 9.0 g/dl, P = 0.02) and RBC transfusion requirement was decreased 50% from 10 units to 5 units.
Biggs and co-workers 10 assigned 91 patients receiving matched-related allogeneic stem cell transplants for leukemia or aplastic anemia to either placebo or rHuEPO (300 units per kg) intravenously three times a week from day 0 to day 42. Study drug was withheld if the hemoglobin rose higher than 12 g/dl but was re-instituted at a 50% lower dose when hemoglobin fell below 12 g/dl. Four patients died prior to day 28 and were not evaluable for engraftment. Median hemoglobin levels and reticulocyte counts did not differ between the two groups before day 14; however, at all other subsequent time points, hemoglobin and reticulocyte counts were significantly higher in the rHuEPO-treated group. On the other hand, RBC transfusion requirement was not improved. This finding may reflect, in part, the short follow-up and the time necessary for rHuEPO response.
Link et al 12 reported a prospective, randomized, placebocontrolled, multi-center European study in both autotransplant (see below) and allotransplant patients comparing placebo vs rHuEPO therapy after transplant. In the allogeneic arm, subjects were given placebo (n = 109) vs rHuEPO (n = 106), administered as 150 units/kg/day via continuous i.v. infusion from the day after marrow infusion until RBC independence for 7 days and a hemoglobin greater than 9 g/dl or until day 41. Erythroid recovery was significantly improved with a median time to RBC transfusion independence of 19 days (range 16 to 22) in the rHuEPO group compared to 27 days (range 22 to Ͼ42) in the placebo group. Reticulocyte recovery was also significantly enhanced by treatment with rHuEPO. Although there was no difference in the transfusion rate in the first 20 days, in the subsequent 3 week period, transfusions were reduced a mean of 1.4 + 2.5 units in the rHuEPO group compared to a mean of 2.7 + 4.0 in the placebo group (P = 0.0004). In a multivariate analysis, patients with severe acute GVHD, age greater than 35 years, severe bleeding or major ABO incompatibility appeared to benefit most from rHuEPO therapy during this time period. Table 3 summarizes the data for rHuEPO after autologous stem cell transplantation. None of the randomized trials showed any benefit for this drug in this patient population. We did a small study in patients with purged autografts which failed to show any benefit of rHuEPO in stimulating erythropoiesis. 13 In the autologous arm of the study Based on an increase in erythroid response in myelodysplastic syndrome patients, Vannucchi et al 7 studied the effect of combining rHuEPO with G-CSF on erythroid recovery after autotransplant. Thirty patients were randomized to receive G-CSF (5 g/kg daily) alone (10 patients), G-CSF plus rHuEPO (n = 10; 150 units/kg daily) or no additional cytokine (n = 10). The rHuEPO group had an improved reticulocyte recovery compared to the G-CSF alone and the control groups but no significant effect on platelet recovery or RBC transfusion requirement.
Autologous stem cell transplant
Chao and colleagues 14 also studied a combination of G-CSF and rHuEPO vs G-CSF alone in lymphoma autotransplant patients. Subjects were randomized to receive rHuEPO (600 units/kg, n = 18 patients) or placebo (n = 17 patients). Study drug was given thrice weekly i.v. beginning 4 weeks before transplant, on the day after bone marrow harvest. Study drug was resumed 1 day after marrow infusion. All patients were given G-CSF (10 g/kg/day) starting on day 1. Although rHuEPO therapy was well-tolerated, no differences were observed in any engraftment parameter or blood product utilization.
rHuEPO in pediatric stem cell transplants
Locatelli and associates 15 compared 20 children treated with rHuEPO during allogeneic (n = 10) and mafosphamide-purged (n = 10) autologous stem cell transplants with untreated historic controls. rHuEPO was given i.v. at a dose of 75 units/kg/day for 30 days after marrow infusion and was well-tolerated in the pediatric population. Erythropoietin response was suppressed after allograft, but normal after autograft. Compared to historic controls, erythroid reconstitution was enhanced in the allogeneic transplant patients given rHuEPO. No effect, however, was seen in the treated autologous transplant patients. The number of RBC units transfused was reduced in the rHuEPO-treated allogeneic transplant patients compared to the historic controls (1.7 Ϯ 1.3 units vs 5.0 Ϯ 3.0 units, P Ͻ 0.05). Platelet transfusions also were decreased (4.0 Ϯ 2.3 units vs 8.4 + 6.8 units, P Ͻ 0.05). No effects were observed on RBC or platelet transfusions in the patients who underwent autograft. Use of rHuEPO would not have reduced the overall cost of transfusion therapy vs transfusions plus drug in either autologous or allogeneic transplant recipients. This group subsequently reported a pilot trial combining G-CSF and rHuEPO in 15 children undergoing allogeneic transplant 16 and compared the transfusion experience to untreated historic controls and patients who received rHuEPO alone. Those patients who received the combined therapy exhibited a decrease in RBC transfusions (1.1 Ϯ 0.7 units) compared to the rHuEPO alone group (2.7 Ϯ 1.2 units) and the historic controls (4.2 Ϯ 2.3 units, P Ͻ 0.001).
rHuEPO therapy in delayed erythropoiesis
Symptomatic chronic anemia and the cost and inconvenience of RBC transfusions may be a significant impediment in patients recovering from the effects of a stem cell transplant. Miller and co-workers 13 reported a pilot trial using rHuEPO therapy in subjects who displayed evidence of delayed erythropoiesis, defined as hemoglobin less than 9 g/dl more than 21 days after stem cell transplantation. Patients were treated with rHuEPO (150 units per kg) three times a week subcutaneously for three weeks. If hemoglobin increased by 1 g/dl over the 3 weeks without transfusion, rHuEPO was withheld, while drug was re-started if hemoglobin fell during the subsequent 3 weeks. Dose was doubled for an additional 3 to 6 weeks if the hemoglobin failed to increase by 1 g/dl during the initial 3 weeks of therapy. Twenty patients were entered (n = 13 allogeneic, n = 7 autologous transplants) at a median of day 44 after stem cell transplant. Two patients withdrew early (one early death due to CMV pneumonia, one patient request). Eleven of the 18 remaining patients received only the 150 units per kg dose level, and 15 of 18 patients (83%) responded by a hemoglobin increase of at least 1 g/dl, or a decrease in transfusion requirement. Nine patients had a complete response, defined as a hemoglobin increase of greater than 2 g/dl, or a 100% decrease in transfusion requirement. Bone marrow cellularity also increased from 4% to 32% in the nine patients who were evaluated. Response to rHuEPO correlated with baseline serum erythropoietin concentration; a complete response was achieved in seven of eight patients who had a baseline erythropoietin level of less than 50 mU/ml whereas only two of nine subjects responded who had a baseline level of greater than 50 mU/ml.
In another pilot trial involving nine transplant recipients more than 50 days after allograft, 17 six patients treated with either 3000 rHuEPO units daily or 12 000 units three times a week responded with at least a 2 g/dl increase in hemoglobin. All three patients who failed to respond had severe GVHD.
In a recent small trial conducted in patients with anemia (median hemoglobin 8.4 g/dl) 35 days after allogeneic bone marrow transplant, a dose of 500 units per kg a week was effective with nine of the 10 patients responding with a 3.6 to 6.1 g/dl increase in hemoglobin. A hemoglobin level of 13 g/dl was reached at a median of 9 weeks and maintained with a median rHuEPO dose of 125 units per kg a week. Quality of life was not assessed.
HuEPO treatment in bone marrow donors
The effect of rHuEPO on the bone marrow donor homologous RBC requirement was evaluated in two studies. Mitus et al 19 treated 11 donors with rHuEPO at a dose of 300 units per kg subcutaneously 5 times a week starting 3 weeks before bone marrow harvest and continuing until 2 weeks after harvest (total 25 doses). One unit of RBCs was collected on the first day of study and then twice weekly for the duration of the study, provided that the hematocrit was greater than 33%. Transplant recipients were given rHuEPO (200 units per kg) daily for 28 days starting 1 day after stem cell infusion. All 11 donors fulfilled phlebotomy requirements and donated a median of 6 (range 4-11) units. After marrow harvest five of the 11 donors used some of their stored autologous units but no homologous blood was transfused to donors. Five of the 11 recipients received only donor-derived RBC transfusions; however, total RBC transfusion requirement during the 28 day study period did not differ between the rHuEPO-treated patients and matched historic controls (8.3 vs 8.1 units, respectively).
York and associates 20 treated two children and eight adult donors with rHuEPO (100 units per kg) daily prior to bone marrow harvest. Eligibility included those who weighed less than 30 kg and did not have an autologous blood unit stored prior to harvest, if they were anemic (hematocrit Ͻ37%) and had only one unit stored, or if a high blood loss was expected during the harvest procedure. After harvest subjects were treated with rHuEPO 150 units per kg three times a week for 2 weeks, or until the hematocrit reached 40%. Each rHuEPO-treated donor was compared to two computer-generated, matched controls. Seven of 10 subjects completed the prescribed course of rHuEPO. No attempt was made to collect RBC units for transfusion to the intended recipient. At the time of marrow donation, the hematocrit increased 18% above the on-study value in donors who were treated with rHuEPO compared to a 6% decrease in the historic controls (P = 0.0001). Furthermore, after harvest the hematocrit decreased 26% in the historic controls compared to only a 4% decrease in the rHuEPOtreated individuals. While the rHuEPO-treated donors did not become anemic and there was no use of homologous blood in this high risk group, none of the adult donors required homologous blood. In the children, however, neither of the rHuEPO-treated donors required blood whereas two of the four controls did.
rHuEPO in stem cell mobilization
In vitro and in vivo studies suggested that rHuEPO may have a role in expansion of the progenitor pool, with or without other growth factors. In animal models Kessinger et al 21 demonstrated that use of EPO alone had a significant stimulatory role on collection of stem cells. Olivieri and colleagues 22 evaluated the effect of G-CSF (5 g/kg/day; n = 18) or G-CSF plus rHuEPO (50 units/kg/day, n = 16 patients) after stem cell mobilization chemotherapy. The patients given rHuEPO had significantly higher erythroid (BFU-E) and myeloid (CFU-GM) progenitor cell content in the apheresis product as well as significantly higher CD34 + cell content. Kessinger et al 21 reported the results of three sequential stem cell mobilization trials assessing the effect of rHuEPO. Eleven patients underwent mobilization using rHuEPO alone (300 units/kg/day), 11 received rHuEPO plus GM-CSF (250 g/m 2 /day) and in 51 only GM-CSF was administered. They found that the combination hematopoietic growth factor regimen required a larger apheresis volume to achieve adequate progenitor cells compared to both of the single growth factor groups. All three types of apheresis product provided similar engraftment times, except that the rHuEPO-alone group had a longer time to neutrophil engraftment.
von Lintig et al 23 published a randomized trial comparing rHuEPO (150 units/kg/day) plus G-SCF (5 g/kg/day) vs G-CSF alone after chemotherapy mobilization for breast cancer autotransplant patients. Total mononuclear cells, CD34
+ cells, or hematopoietic progenitors collected did not differ, nor were any differences in hematopoietic recovery after infusion noted. A non-randomized study evaluated the effect of adding rHuEPO to G-CSF (n = 10) compared to G-CSF alone (n = 10) in healthy allogeneic donors undergoing stem cell mobilization. 24 Ten ABO-matched donors were treated with rHuEPO at 600 units/kg day weekly for 4 weeks before stem cell collection, then biweekly for 3 weeks thereafter. G-CSF (10 g/kg/day) was given to both donor groups. The recipients of the rHuEPO/G-CSF-mobilized cells also received rHuEPO after re-infusion as well as RBC transfusions collected from the donor. Use of rHuEPO resulted in an increase in number of BFU-E mobilized but had no effect on CD34-positive cells in the apheresis product. After re-infusion, time to reticulocyte recovery and RBC transfusion independence was significantly shorter in the rHuEPO-treated donor group. The two donor products did not differ with respect to time to platelet or WBC recovery in the recipient.
Conclusion
Both allogeneic and autologous hematopoietic stem cell transplantation are complicated by a relative erythropoietin deficiency for the degree of anemia. rHuEPO therapy after stem cell transplantation is safe and well-tolerated. Four randomized studies show a decrease in transfusion requirement when rHuEPO is given early after allogeneic stem cell transplant although the magnitude of this benefit was small. In view of the multiple co-morbid factors which develop in the course of a transplant, it has been difficult to show a significant improvement in cost and quality of life as a result of rHuEPO therapy when given early in the treatment course. The use of rHuEPO therapy in the chronic anemia after transplant deserves further investigation, especially in those individuals in whom blood erythropoietin concentration is reduced. Use of this agent can not only result in avoidance of transfusions, but may also play a more important role by enhancing quality of life. rHuEPO also may be useful in children who generally are unable to deposit autologous blood units in blood banks before transplant. On the other hand, the data do not indicate a Bone Marrow Transplantation benefit for use of rHuEPO early after autograft, especially if the transplant recipient was given bone marrow chemically purged in vitro. To date, there have been no published randomized trials which evaluate the effect of rHuEPO on either autologous or allogeneic peripheral blood stem cell transplant. It is likely that studies addressing new formulations of rHuEPO, such as the novel erythropoiesis-stimulating protein, darbepoietin (NESP) will be initiated. This product, a hyperglycosylated analogue of rHuEPO with resulting greater metabolic stability in vivo, has a longer terminal half-life and is likely to need less frequent administration. 25, 26 We then can begin to address important questions including the role of this drug in delayed erythropoiesis and its use after peripheral blood stem cell transplantation.
